Authors
Latest:
How to Transform Real-World Evidence (RWE) Insights with Innovative Data SolutionsOrganizations that focus on improving patient outcomes and reducing healthcare costs rely on real-world data to guide and support their mission. Being able to extract meaningful insights from this data is vital.
Latest:
The Future of Telehealth: Evolving COVID Perspectives Offer CluesNew data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.
Latest:
Amplifying the Patient VoiceJo Fearnhead-Wymbs discusses how and why amplifying the patient voice is driving change in the industry for the better.
Latest:
The Rise of EU Protectionism and M&A in Life SciencesChristine Phillips looks at how an increase in protectionism across the EU member states with respect to foreign direct investment impacts the life sciences sector.
Latest:
The Untapped Potential of Behavioral Science in Medical AffairsHistorically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.
Latest:
AI + Social Media: The Intersection of 2 Contemporary Inventions Takes Physician Engagement to the Next LevelThe two technologies are helping HCPs spread information and collect data in new ways.
Latest:
Mastering Patient Centricity’s Moving Parts: Innovators Share Real-World ExamplesAgility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.
Latest:
From Endemic to POC: The Journey Pharma Marketers Need to TreadThe digital revolution has brought more efficient ways to reach and touch HCPs.
Latest:
From 1990s Business Wisdom to Today’s BioPharma SuccessApplying the McKinsey 7S Framework to TLL and regional marketing teams.
Latest:
Merck Medical Affairs: An Enterprise-Wide Approach to Customer IntelligenceThe importance of enabling customer intelligence at scale.
Latest:
Optimized for Growth? Revenue Management in PharmaAccording to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Latest:
Refining, Rethinking, and Decentralizing Clinical ResearchDecentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.
Latest:
Healthy Planet, Healthy People: How Pharma Can Lead the WayReaching new heights in sustainability a win-win for industry.
Latest:
Janssen, Johns Hopkins Partner on Dermatology Ethnic Skin ProgramJanssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.
Latest:
Harnessing China’s Global OpportunitySy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.
Latest:
AI Can’t Lead. Healthcare Needs LeadersIt’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.
Latest:
Uncovering the Potential of Advanced Analytics in International Price ManagementHow can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
Latest:
FDA’s New Accelerated Approval Draft GuidanceWhat biopharma companies need to know about this evolving regulatory pathway.
Latest:
Pre-Launch Prep for Emerging Biopharmas: Data First, Then the RestMaking early commercial data and analytics decisions for launch cen future-proof their data management.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
Digital-Deal Alignment: Considerations for Tech AgreementsThe eight key areas biopharma manufacturers must stay on top of when planning and executing alliance agreements with prospective digital health partners.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Treating Symptoms to Precision Medicine: The Path ForwardBharat Awsare discusses a paradigm shift he sees in how the industry is designing and discovering new treatments.
Latest:
Why Healthcare Costs are Surging—And What to Do About itIdentifying the inflators and deflators, and the role all stakeholders play.
Latest:
Use Behavioral Science for Better Launch SuccessUnderstanding of human behavior can aid in avoiding pitfalls during launch.
Latest:
SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO AlternativeThe “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
Latest:
Accelerating Market Access with Data-Driven Payer EngagementUsing data visualizations to improve access to payers.
Latest:
10 Market Access Trends to Watch for in 2023As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.
